Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL

Owen O'Connor, MD, PhD
Published: Wednesday, Jan 03, 2018



Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib is seen to be a cleaner, more selective BTK inhibitor, says O’Connor. It hits fewer kinases than ibrutinib, which could mean better tolerability, he adds.
 
SELECTED
LANGUAGE


Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib is seen to be a cleaner, more selective BTK inhibitor, says O’Connor. It hits fewer kinases than ibrutinib, which could mean better tolerability, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic MalignanciesFeb 28, 20192.0
Publication Bottom Border
Border Publication
x